The clinical trial application for the replication deficient monkeypox vaccine developed by Chinese biotechnology has been accepted
On July 13, the application for clinical trial of replication defective monkeypox vaccine independently developed by Sinopharm China Biotech Beijing Institute of Biological Products was officially accepted by the Drug Evaluation Center (CDE) of the National Medical Products Administration.Monkeypox is a kind of zoonotic viral disease caused by Monkeypox virus (MPXV), which is characterized by fever, rash and Lymphadenopathy...
Tech >>
The Zhang Wenhong team is here! The Clinical Research Base of the National Center for Infectious Diseases has settled in Zhuhai
It is reported that the National Center for Infectious Disease Medicine was established with the approval of the National Health Commission, aiming to promote the construction and development of the field of infectious disease medicine nationwide. Zhang Wenhong, Director of the National Center for Infectious Disease Medicine, attended the unveiling ceremony and commented, "Zhuhai has abundant medical resources and a geographical advantage adjacent to Hong Kong and Macao...
Tech >>